Influenza A H1N1 virus hemagglutinin (HA (hemagglutinin))

Influenza A H1N1 virus hemagglutinin is a trimeric glycoprotein located on the surface of the influenza A virus, specifically the H1N1 subtype[1][2][3]. It mediates viral entry into host cells through two critical steps: initial attachment via binding to sialic acid residues on the host cell surface and subsequent fusion of the viral and host membranes triggered by low pH inside endosomes[1][2][3][4]. The HA protein consists of a globular head domain (which contains the receptor-binding site and is the principal target of neutralizing antibodies) and a stem (or stalk) domain responsible for membrane fusion[1][2][4]. HA is highly variable due to antigenic drift, posing major challenges for vaccine design and public health responses[3][5]. The H1N1 hemagglutinin was responsible for the 2009 influenza pandemic and continues to circulate as a major seasonal influenza strain[3]. HA is the central antigenic component in influenza vaccines, eliciting protective immune responses, and is the target of experimental antibody therapies[1][4]. In clinical virology, monitoring antibodies directed against HA is used to assess immunity and vaccine efficacy. Because of its role in viral infectivity, immunogenicity, and antigenic change, it is considered a major therapeutic and diagnostic target in influenza epidemiology[1][2][3][4][5].

Other names

Hemagglutinin (influenza)Influenza hemagglutininInfluenza A virus hemagglutininHA proteinH1 hemagglutinin (when specifying subtype)Hemagglutinin type 1 (H1) protein

Vaccines: Induce antibody response targeting HA, neutralizing viral entry Monoclonal antibodies: Bind HA, block receptor binding or membrane fusion Entry/fusion inhibitors (experimental): Prevent conformational changes required for fusion Note: Most anti-influenza drugs target neuraminidase, not HA[1][3][4]